Biosimilar Labeling: Should FDA Just Throw Up Its Hands And Finalize Guidance?

Brand and generic industries are on opposite sides of spectrum on most issues; there is mutual opposition, however, to the use of a meaningless four-letter suffix in the proper name of a product.